

GLOBAL MARKETS FOR ORPHAN DRUGS



PHM038E
September 2015

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-146-3



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS REPORT	2
CONTRIBUTIONS OF THE REPORT AND FOR WHOM	2
SCOPE OF THE REPORT	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYSTS' CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DIFFERENT KINDS OF ORPHAN DRUGS	10
BIOLOGICAL ORPHAN DRUGS	10
CHEMICAL OR NON-BIOLOGICAL ORPHAN DRUGS	10
GLOBAL DEFINITIONS OF RARE DISEASES	11
U.S.	11
EU	11
TAIWAN	11
JAPAN	11
AUSTRALIA	11
<i>TABLE 1 RARE DISEASES AND THEIR PREVALENCE</i>	11
PERSPECTIVE AND HISTORY OF ORPHAN DRUG ACT	12
<i>TABLE 2 HISTORY OF RARE DISEASES AND ORPHAN DRUG LEGISLATION</i>	13
LEGISLATION IN THE U.S.	14
NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)	14
ORPHAN DRUG ACT	15
<i>TABLE 3 AMENDMENTS OF U.S. ORPHAN DRUG ACT</i>	15
GLOBAL PERSPECTIVE OF ORPHAN DRUGS	16
EUROPE	16
AUSTRALIA	17
SINGAPORE	17
JAPAN	18
TAIWAN	19
CANADA	19
BRAZIL	19
SOUTH KOREA	20
ISRAEL	20
RUSSIA	20

TOPIC	PAGE NO.
KAZAKHSTAN	21
<i>TABLE 4 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN</i>	21
IMPACT OF ORPHAN DRUG ACT	22
<i>TABLE 5 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2014</i>	23
DIFFERENCE BETWEEN ORPHAN DRUGS VS NORMAL DRUGS	23
<i>TABLE 6 DIFFERENCES BETWEEN ORPHAN DRUGS AND NORMAL DRUGS</i>	23
APPLICATION OF APPROVED ORPHAN DRUGS	24
<i>TABLE 7 APPROVED ORPHAN DRUGS AND THEIR THERAPEUTIC USE</i>	24
CHAPTER 4 REGULATORY ASPECTS	28
<i>TABLE 8 MARKET APPROVALS OF ORPHAN DRUGS, 2010-2014</i>	28
RECALLS	36
<i>TABLE 9 RECALLS OF ORPHAN DRUGS, 2010-2014</i>	36
SAFETY ALERTS	37
<i>TABLE 10 SAFETY ALERTS OF ORPHAN DRUGS, 2010-2014</i>	38
CHAPTER 5 NEW DEVELOPMENTS	42
<i>TABLE 11 ORPHAN DRUGS IN CLINICAL TRIALS</i>	42
MERGERS AND ACQUISITIONS	47
<i>TABLE 12 MERGERS AND ACQUISITIONS OF ORPHAN DRUG COMPANIES, 2010-2014</i>	47
CHAPTER 6 MARKET ANALYSIS	52
MARKET BY TYPE	52
MARKET OVERVIEW	53
MARKET REVENUE	54
<i>TABLE 13 GLOBAL REVENUE FOR ORPHAN DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	55
<i>FIGURE 1 GLOBAL REVENUE FOR ORPHAN DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)</i>	55
MARKET SHARES	56
<i>TABLE 14 GLOBAL MARKET SHARE OF MAJOR ORPHAN DRUGS BY TYPE, 2013 (%)</i>	56
<i>FIGURE 2 GLOBAL MARKET SHARE OF MAJOR ORPHAN DRUGS BY TYPE, 2013 (%)</i>	56
MARKET BY REGION	57
MARKET OVERVIEW	57
MARKET REVENUE	58
<i>TABLE 15 GLOBAL REVENUE FOR ORPHAN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	59
<i>FIGURE 3 GLOBAL REVENUE FOR ORPHAN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)</i>	59
MARKET SHARE	60
<i>TABLE 16 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY REGION, 2013 (%)</i>	60
<i>FIGURE 4 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY REGION, 2013 (%)</i>	60
BIOLOGICAL ORPHAN DRUGS	60
MARKET OVERVIEW	61
Ilaris (canakinumab)	62
Proleukin (aldesleukin)	62

TOPIC	PAGE NO.
Nplate (romiplostim)	62
Enbrel (etanercept)	62
Neupogen (filgrastim)	62
Sensipar/Mimpara (cinacalcet)	63
Neulasta (pegfilgrastim)	63
Xgeva (denosumab)	63
Epogen/Procrit (epoetin alfa)	64
Yervoy (ipilimumab)	64
Betaseron/Betaferon (interferon beta-1b)	64
Intron A (interferon Alfa-2b)	64
Kogenate (Recombinant Anti-hemophilic Factor)	65
Remicade (infliximab)	65
Rebetol (ribavirin)	65
Novoseven (Recombinant Coagulation Factor VIIa)	65
Norditropin, Saizen, Genotropin and Nutropin (Somatotropin Recombinant Deoxyribo Nucleic Acid (rDNA))	65
Benefix (Recombinant Coagulation Factor IX)	66
Avastin (bevacizumab)	66
Rituxan/Mab Thera (rituximab)	66
Herceptin (trastuzumab)	67
Aldurazyme (laronidase)	67
Fabrazyme (agalsidase beta)	67
Myozyme/Lumizyme (aglucosidase alpha)	67
Thymoglobulin/Thymoglobulime (Anti-thymocyte Globulin)	68
Mozobil (plerixafor injection)	68
Naglazyme (galsulfase)	68
Soliris (eculizumab)	68
Humira (adalimumab)	68
Elaprase (idursulfase) and VPRIV (velaglucerase alfa)	69
Replagal (agalsidase alfa)	69
Gammagard Liquid (Human Immune Globulin Intravenous)	69
Avonex and Rebif (interferon beta 1-alpha)	69
Other Biological Orphan Drugs	69
MARKET REVENUE	70
<i>TABLE 17 GLOBAL REVENUE OF BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2019 (\$ MILLIONS)</i>	71
MARKET SHARE	72
<i>TABLE 18 GLOBAL MARKET SHARES OF BIOLOGICAL DRUGS, 2013 (%)</i>	73
<i>FIGURE 5 GLOBAL MARKET SHARES OF NON-BIOLOGICAL DRUGS, 2013 (%)</i>	74
MARKET BY REGION	74
Market Overview	75
Market Revenue	76
<i>TABLE 19 GLOBAL REVENUE FOR BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	77
<i>FIGURE 6 GLOBAL REVENUE FOR BIOLOGICAL ORPHAN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)</i>	77
Market Share	77

TOPIC	PAGE NO.
<i>TABLE 20 GLOBAL MARKET SHARE OF BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)</i>	78
<i>FIGURE 7 GLOBAL MARKET SHARE OF BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)</i>	78
NON-BIOLOGICAL ORPHAN DRUGS	78
MARKET OVERVIEW	79
Exjade (deferasirox)	79
Sandostatin LAR (octreotide acetate)	79
Afinitor/Votubia (everolimus)	80
TOBI (tobramycin)	80
Zometa/Zomera/Aclasta/Reclast (zoledronic or zoledronate)	80
Gleevec/Glivec (imatinib mesylate)	80
Copaxone (glatiramer acetate)	81
Tasigna (nilotinib)	81
Sprycel (dasatinib)	81
Onfi (clobazam)	82
Revlimid (lenalidomide)	82
Thalomid (thalidomide)	82
Vidaza (azacitidine for injection)	82
Pomalyst/Imnovid (pomalidomide)	83
Flolan (epoprostenol sodium)	83
Volibris/Letairis/Pulmonext (ambrisentan)	83
Lamictal (lamatrigine)	84
Promacta/Revolade (eltrombopag)	84
Votrient (pazopanib)	84
Velcade (bortezomib)	84
Aromasin (exemestane)	85
Celebrex (Celecoxib)	85
Xalkori (crizotinib)	85
Cerezyme (imiglucerase for injection)	85
Kuvan (6R-BH4)	86
Tracleer (bosentan)	86
Opsumit (macitentan)	86
Zavesca (miglustat)	86
Ventavis (iloprost)	87
Kalydeco (ivacaftor)	87
Treanda (bendamustine), Copaxone (glatiramer)	87
Lialda (mesalamine)	87
Other Non-Biological Orphan Drugs	87
MARKET REVENUE	88
<i>TABLE 21 GLOBAL REVENUE FOR NON-BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2019 (\$ MILLIONS)</i>	90
MARKET SHARE	92
<i>TABLE 22 GLOBAL MARKET SHARES OF NON-BIOLOGICAL DRUGS, 2013 (%)</i>	92
<i>FIGURE 8 GLOBAL MARKET SHARES OF NON-BIOLOGICAL DRUGS, 2013 (%)</i>	94
MARKET BY REGION	94
Market Overview	95
Market Revenue	95

TOPIC	PAGE NO.
<i>TABLE 23 GLOBAL REVENUE FOR NON-BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	96
<i>FIGURE 9 GLOBAL REVENUE FOR NON-BIOLOGICAL ORPHAN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)</i>	96
Market Share	97
<i>TABLE 24 GLOBAL MARKET SHARE OF NON-BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)</i>	97
<i>FIGURE 10 GLOBAL MARKET SHARE OF NON-BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)</i>	97
CHAPTER 7 INDUSTRY STRUCTURE	99
BIOLOGICAL ORPHAN DRUGS	99
MARKET LEADERS	99
<i>TABLE 25 LEADING MANUFACTURERS/SUPPLIERS OF BIOLOGICAL ORPHAN DRUGS, 2013</i>	99
MARKET SHARE	101
<i>TABLE 26 GLOBAL MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR BIOLOGICAL ORPHAN DRUGS, 2013 (%)</i>	101
<i>FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOLOGICAL ORPHAN DRUGS, 2013 (%)</i>	101
NON-BIOLOGICAL ORPHAN DRUGS	102
MARKET LEADERS	102
<i>TABLE 27 LEADING MANUFACTURERS/SUPPLIERS OF NON-BIOLOGICAL ORPHAN DRUGS, 2013</i>	102
MARKET SHARE	104
<i>TABLE 28 GLOBAL MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR NON-BIOLOGICAL ORPHAN DRUGS, 2013 (%)</i>	104
<i>FIGURE 12 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR NON-BIOLOGICAL ORPHAN DRUGS, 2013 (%)</i>	104
CHAPTER 8 MARKET BY APPLICATION	107
GLOBAL ORPHAN DRUGS MARKET BY APPLICATION	107
MARKET OVERVIEW	108
MARKET REVENUE	108
<i>TABLE 29 GLOBAL REVENUES FOR ORPHAN DRUGS BY MEDICAL APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	109
<i>FIGURE 13 GLOBAL REVENUES FOR ORPHAN DRUGS BY MEDICAL APPLICATION, 2012-2019 (\$ MILLIONS)</i>	109
MARKET SHARE	110
<i>TABLE 30 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY MEDICAL APPLICATION, 2013 (%)</i>	110
<i>FIGURE 14 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY MEDICAL APPLICATION, 2013 (%)</i>	110
ONCOLOGY	111
<i>TABLE 31 ONCOLOGY DISEASES</i>	111
Market Overview	112
Market Revenue	115
<i>TABLE 32 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN ONCOLOGY, THROUGH 2019 (\$ MILLIONS)</i>	115
PULMONOLOGY	116

TOPIC	PAGE NO.
<i>TABLE 33 PULMONOLOGY DISEASES</i>	117
Market Overview	117
Market Revenue	118
<i>TABLE 34 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN PULMONOLOGY, THROUGH 2019 (\$ MILLIONS)</i>	119
<i>FIGURE 15 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN PULMONOLOGY, 2012-2019 (\$ MILLIONS)</i>	119
CARDIOLOGY AND NEPHROLOGY	120
<i>TABLE 35 CARDIOLOGY AND NEPHROLOGY DISEASES</i>	120
Market Overview	121
Market Revenue	122
<i>TABLE 36 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN CARDIOLOGY AND NEPHROLOGY, THROUGH 2019 (\$ MILLIONS)</i>	123
<i>FIGURE 16 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN CARDIOLOGY AND NEPHROLOGY, 2012-2019 (\$ MILLIONS)</i>	123
AUTOIMMUNE DISORDERS	124
<i>TABLE 37 AUTOIMMUNE DISORDERS</i>	125
Market Overview	126
Market Revenue	127
<i>TABLE 38 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN AUTOIMMUNE DISORDERS, THROUGH 2019 (\$ MILLIONS)</i>	127
<i>FIGURE 17 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN AUTOIMMUNE DISORDERS, 2012-2019 (\$ MILLIONS)</i>	128
BLOOD DISORDERS	128
<i>TABLE 39 BLOOD DISORDERS</i>	129
Market Overview	129
Market Revenue	130
<i>TABLE 40 GLOBAL REVENUE OF ORPHAN DRUGS USED IN BLOOD DISORDERS, THROUGH 2019 (\$ MILLIONS)</i>	131
<i>FIGURE 18 GLOBAL REVENUE OF ORPHAN DRUGS USED IN BLOOD DISORDERS, 2012-2019 (\$ MILLIONS)</i>	131
NEUROLOGY	132
<i>TABLE 41 NEUROLOGICAL DISEASES</i>	133
Market Overview	133
Market Revenue	134
<i>TABLE 42 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN NEUROLOGICAL DISORDERS, THROUGH 2019 (\$ MILLIONS)</i>	135
<i>FIGURE 19 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN NEUROLOGICAL DISORDERS, 2012-2019 (\$ MILLIONS)</i>	135
HORMONAL DISORDERS AND INFECTIONS	136
<i>TABLE 43 HORMONAL DISORDERS AND INFECTIONS</i>	137
Market Overview	138
Market Revenue	138
<i>TABLE 44 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN HORMONAL DISORDERS AND INFECTIONS, THROUGH 2019 (\$ MILLIONS)</i>	139
<i>FIGURE 20 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN HORMONAL DISORDERS AND INFECTIONS, 2012-2019 (\$ MILLIONS)</i>	139
CHAPTER 9 PATENT ANALYSIS	142
PATENTS BY YEAR	142

TOPIC	PAGE NO.
<i>TABLE 45 NUMBER OF SIGNIFICANT U.S. PATENTS BY YEAR, 2010-2014</i>	143
<i>FIGURE 21 NUMBER OF SIGNIFICANT U.S. PATENTS BY YEAR, 2010-2014</i>	143
PATENTS BY TYPE/CATEGORY	143
<i>TABLE 46 NUMBER OF U.S. PATENTS BY CATEGORY, 2010-2014</i>	143
<i>FIGURE 22 NUMBER OF U.S. PATENTS BY CATEGORY, 2010-2014</i>	144
PATENTS BY COMPANY	144
<i>TABLE 47 NUMBER OF U.S. PATENTS BY COMPANY, 2010-2014</i>	145
PATENTS BY COUNTRY	146
<i>TABLE 48 NUMBER OF U.S. PATENTS BY COUNTRY, 2010-2014</i>	146
<i>FIGURE 23 NUMBER OF U.S. PATENTS BY COUNTRY, 2010-2014 (\$ MILLIONS)</i>	147
<i>TABLE 49 PATENT SHARES BY COUNTRY, 2010-2014 (NO/%)</i>	147
<i>FIGURE 24 PATENT SHARES BY COUNTRY, 2010-2014 (%)</i>	148
PATENTS BY ASSIGNEE	148
<i>TABLE 50 NUMBER OF PATENTS BY ASSIGNEE, 2010-2014</i>	148
<i>FIGURE 25 NUMBER OF PATENTS BY ASSIGNEE, 2010-2014</i>	149
CHAPTER 10 CURRENT TRENDS	151
FACTORS THAT ARE BOOSTING THE ORPHAN DRUG MARKET	151
ORPHAN DRUG ACT AND SIMILAR LEGISLATIONS	151
TECHNOLOGICAL ADVANCES AND GENETIC CODE	151
GENERIC COMPETITION	152
PATENT EXPIRATIONS	152
PREMIUM PRICING	152
INNOVATIONS IN MANUFACTURING TECHNOLOGIES	152
COLLABORATIONS AND LICENSING AGREEMENTS	153
MERGERS AND ACQUISITIONS	154
CHALLENGES	154
LACK OF TRAINED PROFESSIONALS	154
VULNERABLE TARGET GROUPS	155
MULTIPLE USAGES	155
REGULATORY CHALLENGE	155
CHAPTER 11 COMPANY PROFILES	157
ACORDA THERAPEUTICS	157
ACTELION PHARMACEUTICALS LTD.	157
AEGERION PHARMACEUTICALS	158
ALEXION PHARMACEUTICALS	158
AMGEN	158
BAXTER INTERNATIONAL	159
BAYER HEALTHCARE PHARMACEUTICALS	159
BIOGEN IDEC	160
BIOMARIN PHARMACEUTICAL INC.	160
BRISTOL-MYERS SQUIBB	161
CANGENE CORP.	161
CELGENE	162
GENZYME	162
GILEAD SCIENCES INC.	163

TOPIC	PAGE NO.
GLAXOSMITHKLINE	163
JOHNSON & JOHNSON	164
LUNDBECK LLC	164
MERCK	165
NOVARTIS	165
NOVO NORDISK INC.	166
ONYX THERAPEUTICS	166
PFIZER INC.	167
ROCHE	167
SEATTLE GENETICS	168
SHIRE PLC	169
TAKEDA PHARMACEUTICAL U.S.A. INC.	170
VECTURA GROUP PLC	170
VERTEX PHARMACEUTICALS	170
CHAPTER 12 ABBREVIATIONS	173

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 RARE DISEASES AND THEIR PREVALENCE	11
TABLE 2 HISTORY OF RARE DISEASES AND ORPHAN DRUG LEGISLATION	13
TABLE 3 AMENDMENTS OF U.S. ORPHAN DRUG ACT	15
TABLE 4 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN	21
TABLE 5 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2014	23
TABLE 6 DIFFERENCES BETWEEN ORPHAN DRUGS AND NORMAL DRUGS	23
TABLE 7 APPROVED ORPHAN DRUGS AND THEIR THERAPEUTIC USE	24
TABLE 8 MARKET APPROVALS OF ORPHAN DRUGS, 2010-2014	28
TABLE 9 RECALLS OF ORPHAN DRUGS, 2010-2014	36
TABLE 10 SAFETY ALERTS OF ORPHAN DRUGS, 2010-2014	38
TABLE 11 ORPHAN DRUGS IN CLINICAL TRIALS	42
TABLE 12 MERGERS AND ACQUISITIONS OF ORPHAN DRUG COMPANIES, 2010-2014	47
TABLE 13 GLOBAL REVENUE FOR ORPHAN DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)	55
TABLE 14 GLOBAL MARKET SHARE OF MAJOR ORPHAN DRUGS BY TYPE, 2013 (%)	56
TABLE 15 GLOBAL REVENUE FOR ORPHAN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)	59
TABLE 16 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY REGION, 2013 (%)	60
TABLE 17 GLOBAL REVENUE OF BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2019 (\$ MILLIONS)	71
TABLE 18 GLOBAL MARKET SHARES OF BIOLOGICAL DRUGS, 2013 (%)	73
TABLE 19 GLOBAL REVENUE FOR BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)	77
TABLE 20 GLOBAL MARKET SHARE OF BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)	78
TABLE 21 GLOBAL REVENUE FOR NON-BIOLOGICAL ORPHAN DRUGS BY ACTIVE INGREDIENT, THROUGH 2019 (\$ MILLIONS)	90
TABLE 22 GLOBAL MARKET SHARES OF NON-BIOLOGICAL DRUGS, 2013 (%)	92
TABLE 23 GLOBAL REVENUE FOR NON-BIOLOGICAL ORPHAN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)	96
TABLE 24 GLOBAL MARKET SHARE OF NON-BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)	97
TABLE 25 LEADING MANUFACTURERS/SUPPLIERS OF BIOLOGICAL ORPHAN DRUGS, 2013	99
TABLE 26 GLOBAL MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR BIOLOGICAL ORPHAN DRUGS, 2013 (%)	101
TABLE 27 LEADING MANUFACTURERS/SUPPLIERS OF NON-BIOLOGICAL ORPHAN DRUGS, 2013	102
TABLE 28 GLOBAL MARKET SHARE OF THE MANUFACTURERS/SUPPLIERS FOR NON-BIOLOGICAL ORPHAN DRUGS, 2013 (%)	104
TABLE 29 GLOBAL REVENUES FOR ORPHAN DRUGS BY MEDICAL APPLICATION, THROUGH 2019 (\$ MILLIONS)	109
TABLE 30 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY MEDICAL APPLICATION, 2013 (%)	110
TABLE 31 ONCOLOGY DISEASES	111

TABLE HEADING	PAGE NO.
TABLE 32 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN ONCOLOGY, THROUGH 2019 (\$ MILLIONS)	115
TABLE 33 PULMONOLOGY DISEASES	117
TABLE 34 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN PULMONOLOGY, THROUGH 2019 (\$ MILLIONS)	119
TABLE 35 CARDIOLOGY AND NEPHROLOGY DISEASES	120
TABLE 36 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN CARDIOLOGY AND NEPHROLOGY, THROUGH 2019 (\$ MILLIONS)	123
TABLE 37 AUTOIMMUNE DISORDERS	125
TABLE 38 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN AUTOIMMUNE DISORDERS, THROUGH 2019 (\$ MILLIONS)	127
TABLE 39 BLOOD DISORDERS	129
TABLE 40 GLOBAL REVENUE OF ORPHAN DRUGS USED IN BLOOD DISORDERS, THROUGH 2019 (\$ MILLIONS)	131
TABLE 41 NEUROLOGICAL DISEASES	133
TABLE 42 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN NEUROLOGICAL DISORDERS, THROUGH 2019 (\$ MILLIONS)	135
TABLE 43 HORMONAL DISORDERS AND INFECTIONS	137
TABLE 44 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN HORMONAL DISORDERS AND INFECTIONS, THROUGH 2019 (\$ MILLIONS)	139
TABLE 45 NUMBER OF SIGNIFICANT U.S. PATENTS BY YEAR, 2010-2014	143
TABLE 46 NUMBER OF U.S. PATENTS BY CATEGORY, 2010-2014	143
TABLE 47 NUMBER OF U.S. PATENTS BY COMPANY, 2010-2014	145
TABLE 48 NUMBER OF U.S. PATENTS BY COUNTRY, 2010-2014	146
TABLE 49 PATENT SHARES BY COUNTRY, 2010-2014 (NO/%)	147
TABLE 50 NUMBER OF PATENTS BY ASSIGNEE, 2010-2014	148

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)	8
FIGURE 1 GLOBAL REVENUE FOR ORPHAN DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)	55
FIGURE 2 GLOBAL MARKET SHARE OF MAJOR ORPHAN DRUGS BY TYPE, 2013 (%)	56
FIGURE 3 GLOBAL REVENUE FOR ORPHAN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)	59
FIGURE 4 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY REGION, 2013 (%)	60
FIGURE 5 GLOBAL MARKET SHARES OF NON-BIOLOGICAL DRUGS, 2013 (%)	74
FIGURE 6 GLOBAL REVENUE FOR BIOLOGICAL ORPHAN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)	77
FIGURE 7 GLOBAL MARKET SHARE OF BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)	78
FIGURE 8 GLOBAL MARKET SHARES OF NON-BIOLOGICAL DRUGS, 2013 (%)	94
FIGURE 9 GLOBAL REVENUE FOR NON-BIOLOGICAL ORPHAN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)	96
FIGURE 10 GLOBAL MARKET SHARE OF NON-BIOLOGICAL ORPHAN DRUG MARKET BY REGION, 2013 (%)	97
FIGURE 11 GLOBAL MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR BIOLOGICAL ORPHAN DRUGS, 2013 (%)	101
FIGURE 12 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR NON-BIOLOGICAL ORPHAN DRUGS, 2013 (%)	104
FIGURE 13 GLOBAL REVENUES FOR ORPHAN DRUGS BY MEDICAL APPLICATION, 2012-2019 (\$ MILLIONS)	109
FIGURE 14 GLOBAL MARKET SHARE OF ORPHAN DRUGS BY MEDICAL APPLICATION, 2013 (%)	110
FIGURE 15 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN PULMONOLOGY, 2012-2019 (\$ MILLIONS)	119
FIGURE 16 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN CARDIOLOGY AND NEPHROLOGY, 2012-2019 (\$ MILLIONS)	123
FIGURE 17 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN AUTOIMMUNE DISORDERS, 2012-2019 (\$ MILLIONS)	128
FIGURE 18 GLOBAL REVENUE OF ORPHAN DRUGS USED IN BLOOD DISORDERS, 2012-2019 (\$ MILLIONS)	131
FIGURE 19 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN NEUROLOGICAL DISORDERS, 2012-2019 (\$ MILLIONS)	135
FIGURE 20 GLOBAL REVENUE FOR ORPHAN DRUGS USED IN HORMONAL DISORDERS AND INFECTIONS, 2012-2019 (\$ MILLIONS)	139
FIGURE 21 NUMBER OF SIGNIFICANT U.S. PATENTS BY YEAR, 2010-2014	143
FIGURE 22 NUMBER OF U.S. PATENTS BY CATEGORY, 2010-2014	144
FIGURE 23 NUMBER OF U.S. PATENTS BY COUNTRY, 2010-2014 (\$ MILLIONS)	147
FIGURE 24 PATENT SHARES BY COUNTRY, 2010-2014 (%)	148
FIGURE 25 NUMBER OF PATENTS BY ASSIGNEE, 2010-2014	149